Blood Results in Clinical Practice: A Practical Guide to Interpreting Blood Test Results - 2nd ed. (2019)

BNF is a joint publication of the British Medical Association and the Royal Pharmaceutical Society. It is issued under the auspices of a Joint Formulation Committee composed of representatives of two professional bodies, the British Health Departments, the Agency for the Regulation of Medicines and Medical Products and the manufacturer of national guidelines. Dental Advisory Group oversees the preparation of dental and oral treatment management advice; the group includes representatives of the British Dental Association and representatives of the British Health Departments. The Prescribing Physicians Advisory Group provides advice on nurse-related content and includes representatives from different parts of the nursing community and the UK's health departments. Drug information is taken from the manufacturers' product literature, medical and pharmaceutical literature, UK health departments, regulators and professional bodies. The advice is taken from the clinical literature and reflects, where possible, evaluations of evidence from a variety of sources. BNF also considers national guidelines and increased safety care to be authoritative. In addition, the newsroom received advice in all areas of treatment from specialist clinics; this ensures that BNF's recommendations are relevant to practice.

Many of the unprotected titles used in this book are the titles of the monographs of the European Pharmacopoeia, the British Pharmacopoeia or the British Pharmaceutical Code 1973. In such cases, the products must comply with the standard (if any) of the relevant publication, if necessary. . under the Medicinal Products for Human Use Regulation 2012. Custom titles Medicines should only be prescribed when they are needed, and in any case the benefits of drug administration should be considered in relation to the associated risk. This is especially important during pregnancy, when the risk to the mother and fetus must be taken into account. Pharmaceutical Preformulation and Formulation: a Practical Guide from Candidate Drug Selection to Commercial Dosage Form - 2nd ed. (2009)

Ibrutinib (Imbruvica®): new risk minimisation measures, including dose modification recommendations, due to the increased risk for serious cardiac events Mylan. Acamprosate 333 mg Gastro-resistant Tablets SmPC. 2020 [cited 2020 Dec 4]Available from: https://www.medicines.org.uk/emc/product/2729/smpc As an example, here's a reference for the whole print BNF in Harvard format (remember, though, that you will probably be referencing a specific entry): Pharmaceutical Excipients: Properties, Functionality and Applications in Research and Industry (2017) Pholcodine-containing cough and cold medicines: withdrawal from UK market as a precautionary measureMylan (2020) Acamprosate 333 mg Gastro-resistant Tablets SmPC. Available at: https://www.medicines.org.uk/emc/product/2729/smpc (Accessed: 4 December 2020). Names used as monograph names may be used freely in the United Kingdom, but may be banned in other countries. On all programmes, it is essential to reference everything you use in your written work. Any time you quote from, summarise, paraphrase or discuss something you have read, listened to or watched, you should reference it. This tells the reader where your information comes from, and it ensures that you are not plagiarising (using someone else's words or work without credit).